Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados 60 (2) Autor Blatt,Carine Raquel (2) Farias,Mareni Rocha (2) Mühlberger,Nikolai (1) Peres,Kaite Cristiane (1) Rosa,Junior André da (1) Siebert,Uwe (1) Silva,Rochele (1) Storb,Bernd (1) Storb,Bernd Heinrich (1) Mais... Palavra-chave Effectiveness (1) Hepatitis C (1) Hepatitis C Chronic (1) Hepatitis C chronic/treatment (1) Hepatitis C/ treatment/cost-effectiveness evaluation (1) Interferon alfa-2a (1) Interferon alfa-2b (1) Interferon alpha/Hepatitis C treatment (1) Peginterferon alpha/Hepatitis C treatment (1) Ribavirin/Hepatitis C treatment (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2014 (1) 2012 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin 60 Rosa,Junior André da; Blatt,Carine Raquel; Peres,Kaite Cristiane; Storb,Bernd Heinrich; Silva,Rochele; Farias,Mareni Rocha. This study aimed to evaluate the rate of sustained virological response (SVR) and the clinical and treatment characteristics of patients with chronic hepatitis C (CHC). A retrospective uncontrolled cohort study was conducted among patients who received treatment for CHC between 2005 and 2008 attended at the Center for the Application and Monitoring of Injectable Medications, in Florianopolis, SC, Brazil. The inclusion criteria were: patients over 18 years of age, with a confirmed diagnosis of chronic hepatitis C according to Brazilian guidelines, treated with PEG-IFN alfa-2a or 2b associated with RBV. A total of 188 patients were included in the study: 70% men, 59% genotype 1, 27% coinfected with HIV, 31% with cirrhosis. The SVR rate, calculated by... Tipo: Info:eu-repo/semantics/article Palavras-chave: Hepatitis C; Hepatitis C Chronic; Effectiveness; Interferon alfa-2a; Interferon alfa-2b. Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000200002 Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment 60 Blatt,Carine Raquel; Storb,Bernd; Mühlberger,Nikolai; Farias,Mareni Rocha; Siebert,Uwe. Brazilian Guidelines to HCV treatment (2007) recommended that the first choice treatment for patients with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) plus ribavirin (RBV) for 24 weeks. The aim of this study is compare the cost and effectiveness to Hepatitis C treatment in patients with genotype 2 or 3 of peginterferon alpha (PEG) as the first choice of treatment within PEG for those that do not respond to IFN. The target population is CHC patients with genotype 2 or 3 in Brazil. The interventions are: PEG-SEC (first IFN plus RBV for 24 weeks, after, for non-responders and relapsers subsequently PEG plus RBV for 48 weeks); PEG-FIRST24 (PEG+RBV for 24 weeks). The type of the study is cost-effectiveness analysis. The data sources... Tipo: Info:eu-repo/semantics/article Palavras-chave: Hepatitis C chronic/treatment; Interferon alpha/Hepatitis C treatment; Ribavirin/Hepatitis C treatment; Peginterferon alpha/Hepatitis C treatment; Hepatitis C/ treatment/cost-effectiveness evaluation. Ano: 2014 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000200345 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco